Free Trial

Regulus Therapeutics (RGLS) News Today

Regulus Therapeutics logo
$1.53 -0.06 (-3.77%)
(As of 05:45 PM ET)
Regulus Therapeutics Inc. stock logo
Fmr LLC Has $515,000 Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS)
Fmr LLC trimmed its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 83.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 328,157 shares of the biopharmaceutical company's stock after
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have assig
Regulus Therapeutics Inc. stock logo
Point72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)
Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 893,762 shares of the biopharmaceutical comp
Regulus Therapeutics Inc. stock logo
RA Capital Management L.P. Decreases Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)
RA Capital Management L.P. trimmed its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 87.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 766,834 shares of the biopharmaceutical comp
Regulus Therapeutics Inc. stock logo
6,467,802 Shares in Regulus Therapeutics Inc. (NASDAQ:RGLS) Purchased by NEA Management Company LLC
NEA Management Company LLC purchased a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 6,467,802 shares of the biopharmaceutical company's stock, valued at ap
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have giv
Regulus Therapeutics Reports Q3 2024 Financial Results
Regulus Therapeutics Inc. stock logo
What is HC Wainwright's Forecast for RGLS FY2024 Earnings?
Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for shares of Regulus Therapeutics in a note issued to investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the b
Regulus Therapeutics Inc. stock logo
HC Wainwright Reaffirms Buy Rating for Regulus Therapeutics (NASDAQ:RGLS)
HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday.
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Wednesday.
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the
Regulus Therapeutics Inc. stock logo
HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS)
HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Tuesday.
Regulus Therapeutics Inc. stock logo
CVI Holdings LLC Cuts Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)
CVI Holdings LLC decreased its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 71.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 401,012 shares of the biopharmaceutical company's stock after selling 1,005,2
Regulus Therapeutics Inc. stock logo
StockNews.com Upgrades Regulus Therapeutics (NASDAQ:RGLS) to "Sell"
StockNews.com raised shares of Regulus Therapeutics to a "sell" rating in a research note on Tuesday.
Regulus Therapeutics Inc (7RG0.SG)
Regulus Therapeutics Inc. stock logo
Vanguard Group Inc. Boosts Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)
Vanguard Group Inc. boosted its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 158.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 740,215 shares of the biopharmaceutical company's stock aft
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Reaffirmed by Oppenheimer
Oppenheimer reiterated an "outperform" rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday.
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics Inc. Forecasted to Earn Q2 2025 Earnings of ($0.20) Per Share (NASDAQ:RGLS)
Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Regulus Therapeutics in a note issued to investors on Thursday, August 8th. Leerink Partnrs analyst J. Schwartz expects that the biopharmaceutical com
Regulus Therapeutics Inc. stock logo
HC Wainwright Reiterates "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS)
HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research note on Friday.
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at Oppenheimer
Oppenheimer initiated coverage on shares of Regulus Therapeutics in a research note on Friday. They issued an "outperform" rating and a $7.00 target price for the company.
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Update
Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the target of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 4,340,000 shares, a decline of 18.1% from the June 30th total of 5,300,000 shares. Approximately 8.2% of the company's shares are short sold. Based on an average daily volume of 817,600 shares, the days-to-cover ratio is presently 5.3 days.
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy r
Regulus Therapeutics Inc. stock logo
CVI Holdings LLC Makes New $4.05 Million Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)
CVI Holdings LLC bought a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,406,250 shares of the biopharmaceutical company's stock, valued at ap
Regulus Therapeutics Inc. stock logo
Short Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Grows By 48.0%
Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 5,300,000 shares, an increase of 48.0% from the June 15th total of 3,580,000 shares. Based on an average trading volume of 798,700 shares, the days-to-cover ratio is presently 6.6 days. Approximately 10.0% of the shares of the company are short sold.
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics Inc. to Post Q1 2025 Earnings of ($0.20) Per Share, HC Wainwright Forecasts (NASDAQ:RGLS)
Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Regulus Therapeutics in a research note issued on Tuesday, June 25th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will pos
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics (NASDAQ:RGLS) PT Raised to $28.00
Canaccord Genuity Group boosted their price target on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a "buy" rating in a research report on Tuesday.
Regulus Therapeutics Inc. stock logo
Regulus Therapeutics (NASDAQ:RGLS) Stock Crosses Above Two Hundred Day Moving Average of $1.87
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200-Day Moving Average of $1.87
Get Regulus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

RGLS Media Mentions By Week

RGLS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RGLS
News Sentiment

0.96

0.59

Average
Medical
News Sentiment

RGLS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RGLS Articles
This Week

3

1

RGLS Articles
Average Week

Get Regulus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:RGLS) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners